Cyclin E1 is a strong prognostic marker for death from lymph node negative breast cancer. A population-based case-control study

Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment

(2011) Peter A Fasching et al.   BMC CANCER

P272 Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC), followed by docetaxel (T) with or without capecitabine (X), in high-risk early breast cancer (EBC): efficacy results

(2011) J. O'Shaughnessy et al.   BREAST

Trends in the survival of patients diagnosed with breast cancer in the Nordic countries 1964–2003 followed up to the end of 2006

(2010) Laufey Tryggvadóttir et al.   ACTA ONCOLOGICA

The Oncotype DX Recurrence Score Is Correlated With a Composite Index Including Routinely Reported Pathobiologic Features

(2010) Joseph Geradts et al.   CANCER INVESTIGATION

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

(2009) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Cyclin A Is a Proliferative Marker with Good Prognostic Value in Node-Negative Breast Cancer

(2009) C. Ahlin et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Aberrant expression of cyclin E in low-risk node negative breast cancer

(2008) Cecilia Ahlin et al.   ACTA ONCOLOGICA

Familial Breast Cancers without Mutations in BRCA1 or BRCA2 Have Low Cyclin E and High Cyclin D1 in Contrast to Cancers in BRCA Mutation Carriers

(2008) K. Aaltonen et al.   CLINICAL CANCER RESEARCH